Technology
Health
Biotechnology

Molecular Templates

$7.79
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (2.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MTEM and other stocks, options, ETFs, and crypto commission-free!

About

Molecular Templates, Inc. Common Stock, also called Molecular Templates, is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. Read More Its product pipeline includes MT-3724, TAK-169, MT-5111, and MT-6035. The company was founded on October 17, 2001 and is headquartered in Austin, TX.

Employees
68
Headquarters
Austin, Texas
Founded
2001
Market Cap
286.33M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
142.48K
High Today
$7.85
Low Today
$7.50
Open Price
$7.55
Volume
26.41K
52 Week High
$7.90
52 Week Low
$3.19

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Pharmaceutical
US

News

Yahoo FinanceMay 13

Molecular Templates, Inc. Reports First Quarter 2019 Financial Results

AUSTIN, Texas, May 13, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today reported financial results for the first quarter of 2019. As of March 31, 2019, Molecular’s cash and investments totaled $84 million, and is expected to fund operations int...

42
Yahoo FinanceMay 6

Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know

The market expects Molecular Templates (MTEM) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

62

Earnings

-$0.36
-$0.26
-$0.16
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.22 per share
Actual
-$0.17 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.